New D-MARDs

Biologic and Targeted Synthetic D-MARDs 

1) Introduction

Biologic D-MARDs are engineered from living cells to target specific immune pathways that drive arthritis and related autoimmune disease. They differ from conventional D-MARDs (like methotrexate) by focusing on a single cytokine or cell-signal rather than broadly suppressing immunity.
Targeted synthetic D-MARDs (ts D-MARDs) – notably the JAK inhibitors – are oral small molecules that inhibit the JAK-STAT pathway used by multiple cytokines at once.
These medicines can be highly effective and reduce joint damage, yet they carry meaningful risks, high costs, monitoring needs, and access hurdles.

Use medicines strategically (often short- to medium-term), while addressing root drivers with lifestyle so that you can reduce medication (under medical supervision) once inflammation is low.

2) Tumor Necrosis Factor (TNF) Inhibitors

Examples: Adalimumab (Humira) and biosimilars; Etanercept (Enbrel); Infliximab (Remicade) and biosimilars; Golimumab (Simponi/Simponi Aria); Certolizumab pegol (Cimzia)
Mechanism: Neutralise TNF-α, a master inflammatory cytokine in synovium and bone.
Benefits (typical): Rapid pain and stiffness relief, better function, reduced flare frequency, and slowed radiographic progression in responders. Effective in RA, PsA, axial spondyloarthritis (A.S.), and some extra-articular diseases (IBD, uveitis).
Common side effects: Injection and infusion reactions, headache, fatigue, URIs.
Serious and long-term risks (class): Serious infections (TB, invasive fungal, opportunistic), shingles; HBV reactivation; rare lymphomas (signal strongest in IBD youth on combination immunosuppression); demyelinating disorders; worsening heart failure warnings for some agents; drug-induced lupus-like reactions. Increased risk of skin cancers. 
Monitoring: TB and HBV screening before start; vaccination review; periodic CBC and LFT ± CRP and ESR; vigilance for infection, neurologic or HF symptoms.
Indicative US list/WAC cost: Commonly ~US $4,000 to $9,000 per month brand-list before insurance; adalimumab biosimilars and programs can cut patient costs dramatically. Etanercept often falls ~US $1,800 to $4,000 per month at list depending on pack and strength; real patient cost varies widely.

Agent notes (high-level):

• Adalimumab: Broadly applied  (RA, PsA, A.S., IBD, uveitis). Immunogenicity mitigated by combination with methotrexate in RA.

• Etanercept (weekly): receptor-fusion protein; convenient weekly dosing; HF and demyelination cautions apply.

• Infliximab (Infusion): weight-based infusion; higher immunogenicity without MTX (RA); infusion center logistics and facility fees.

• Golimumab (Injection monthly or IV): monthly convenience; IV “Aria” requires infusion setting.

• Certolizumab (Injection): Sometimes preferred in pregnancy planning due to minimal placental transfer late in gestation.

Personally I used Enbrel (Etanercept) on and off as needed until I worked out all my inflammation triggers and the will power to follow my own advise. It was tempting to use the Enbrel – so that I could get away with eating more problematic foods, but when I developed melanomas, I decided to be strict and follow my lifestyle protocols and stop all medication. I want to give you the information needed to have this possible option too. 

3) Interleukin-6 (IL-6) Inhibitors

Examples: Tocilizumab (Actemra; infusion or injection), Sarilumab (Kevzara; injection)
Mechanism: Block IL-6 receptor signalling (IL-6 is a key driver of acute-phase response, anaemia of chronic disease, fatigue).
Benefits: Strong RA efficacy (mono or with MTX), helpful after TNF failure; improves systemic symptoms (fatigue, fever), and normalises CRP.
Common side effects: URIs, injection reactions (SC), headache.
Serious and long-term risks: Serious infections; neutropenia, thrombocytopenia; transaminase elevations; lipid increases; rare GI perforation (higher in diverticular disease and with NSAIDs or steroids).
Monitoring: CBC with diff, LFTs, fasting lipids; TB/HBV screening; avoid live vaccines.
Indicative US list and WAC cost: Often ~US$1,500–$5,000 per month equivalent, depending on route, dose, and body weight.

4) Interleukin-17 (IL-17) Inhibitors

Examples: Secukinumab (Cosentyx), Ixekizumab (Taltz), Brodalumab (Siliq)
Mechanism: Block IL-17A (or IL-17 receptor) within the Th17 axis.
Benefits: Particularly effective for psoriatic arthritis and axial spondyloarthritis such as A.S., (strong enthesitis and axial pain improvements) and for psoriasis skin disease.
Common side effects: Nasopharyngitis, injection reactions, headache.
Serious and long-term risks: Mucocutaneous candidiasis; new or worsening IBD has been reported (caution – avoid in Crohn’s and UC unless specifically indicated by gastroenterologist). Brodalumab carries a boxed warning for suicidal ideation and behaviour (REMS).
Monitoring: Infection vigilance; IBD history review; avoid live vaccines.
Indicative US list and WAC cost: Commonly ~US$1,500–$2,500 per month equivalent maintenance at list.

5) Interleukin-12 & 23 and IL-23 Inhibitors

Examples: Ustekinumab (Stelara; IL-12 & 23), Guselkumab (Tremfya; IL-23), Risankizumab (Skyrizi; IL-23)
Mechanism: Modulate the Th1, Th17 axis by blocking IL-12 & 23, dampening downstream IL-17 activity.
Benefits: Excellent for psoriasis; useful in PsA (peripheral disease) and for IBD (ustekinumab, risankizumab in Crohn’s).
Common side effects: Injection reactions, URIs, headache, fatigue.
Serious and long-term risks: Serious infections (class); malignancy signals monitored but not clearly elevated across the class; TB and HBV screening as standard.
Monitoring: Infection vigilance; routine labs.
Indicative US list cost: High per-dose list prices (infrequent dosing) that translate to ~US $10000 to $20000 per 8 to 12-week cycle at list before insurance.

6) B-Cell Depleting Therapy

Example: Rituximab (Rituxan; biosimilars available)
Mechanism: Anti-CD20 monoclonal antibody depleting B cells.
Benefits: Effective in RA after TNF failure; also used in ANCA-associated vasculitis and selected autoimmune diseases; dosing is intermittent (e.g., every 6–12 months) in responders.
Common side effects: Infusion reactions (premedication routine), fatigue.
Serious/long-term risks: HBV reactivation (screen meticulously); serious infections; rare PML (JC virus); severe mucocutaneous reactions (rare).
Monitoring: HBV serology prior to therapy and during follow-up; CBC; infection vigilance.
Indicative US list cost: Highly variable; drug plus facility can total ~US $5000 to $15000 per infusion at list; biosimilars may lower acquisition cost.

7) T-Cell Co-stimulation Blocker

Example: Abatacept (Orencia; IV/SC)
Mechanism: CTLA-4-Ig fusion protein that blocks CD80/86–CD28 interaction, preventing full T-cell activation.
Benefits: Option across RA spectrum (and JIA); sometimes chosen where infection profile favours it clinically.
Common side effects: Headache, nausea, URIs, injection reactions.
Serious/long-term risks: Serious infections; do not combine with TNF inhibitors (higher infection risk without added benefit). COPD exacerbations reported in some.
Monitoring: Standard infection screening; routine labs per clinician.
Indicative US list cost: Frequently ~US $3000 to $6,000 per month equivalent at list; assistance programs can markedly reduce patient cost.

8) JAK Inhibitors (Targeted Synthetic DMARDs)

Examples: Tofacitinib (Xeljanz/XR), Baricitinib (Olumiant), Upadacitinib (Rinvoq), Filgotinib (Jyseleca; region-dependent availability)
Mechanism: Oral small molecules that inhibit JAK-STAT signalling used by many cytokines (e.g., IL-2, IL-6, IL-12, IL-23, interferons, GM-CSF). They do not directly block TNF-α but can indirectly lower network inflammation.
Benefits: Rapid symptom relief; effective after biologic failure; convenient oral dosing; strong data in RA and PsA (agent-dependent), plus other immune diseases.
Common side effects: URIs, headache, acne, nausea, elevated lipids and liver enzymes.
Serious/long-term risks (class boxed warnings in several regions): Major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, serious infections (incl. herpes zoster) and increased mortality in higher-risk cohorts (older age, smoking, CV/cancer risk).
Monitoring: Lipids (baseline and after start), CBC, LFTs; screen TB/HBV; zoster vaccination review; careful risk stratification before initiation.
Indicative US listcost: Commonly ~US $4000 to $7000 per month at list.

9) Monitoring and Safety

• Before starting: The following are common –  TB screening (IGRA/TST), HBV serology (HBsAg, anti-HBc, anti-HBs), vaccination status (influenza, pneumococcal, COVID-19, recombinant zoster, hepatitis B). Avoid live vaccines during biologics, JAK therapy.

• During therapy: CBC with differential; LFTs; lipids for IL-6/JAK agents; CRP/ESR and disease scores for treat-to-target; clinical surveillance for infection (fever, cough, shingles), neurologic symptoms, heart failure symptoms, GI perforation risk with IL-6 blockers.

• Drug interactions & combos: Avoid combining two biologics or biologic + JAK outside specialist protocols; abatacept + TNF is not recommended due to infections without added efficacy.

10) Costs and Access 

• List WAC prices are high across the class. Biosimilars (particularly for adalimumab and infliximab) can drop acquisition costs substantially; formularies may prefer one product.

• Infusions add facility and administration charges; site of care (hospital vs ambulatory center) changes pricing dramatically.

• Assistance programs and insurer copay accumulators vary – always check current options. Real patient costs range from $0 to a few hundred per month after assistance to many thousands without coverage.

11) Some of the Lifestyle Changes that Calm The Same Pathways

• Dietary Omega Balance.
  High omega-6 to omega-3 ratio intake up-regulates TNF-α, IL-1β, and IL-6. Shifting toward fish and ALA-rich plant sources and trimming industrial seed oils can lower the same mediators targeted by TNF and IL-6 blockers.
  
  
• Dietary Triggers 
  Removing Dietary triggers, toxins and pathogens will lower inflammation.
  
  
• Chronic Stress.
  Persistent stress elevates TNF-α, IL-6, interferon-γ. Meditation, breathwork, psychotherapy, social connection, nature time, and restorative routines reduce these signals – overlapping with the targets of TNF, IL-6 and JAK-pathway drugs.
  
  
• Gut Dysbiosis & Leaky Gut.
  Microbiome imbalance increases gut permeability. Bacterial products like LPS drive TNF-α, IL-1β and IL-23 leading to Th17 and IL-17 activation. Fibre-rich diets, fermented foods (as tolerated), and careful removal of individual trigger foods help normalise these pathways – similar to the targets of TNF, IL-17, IL23, and JAK agents.
  
  
• Visceral Fat & Obesity.
  Adipose tissue is immunologically active, secreting TNF-α and IL-6. Sustainable fat loss through nutrition, movement, sleep, and stress work lowers the same mediators addressed by TNF and IL-6 inhibition.
  
  
• Fasting.
  Fasting and restricted time eating lowers inflammation. 
  
  
• Vitamin D Status.
  Low vitamin D biases toward IL-17 & IL-23 activity and reduced T-reg function. Correcting deficiency supports a shift away from Th17-dominant inflammation (converging with IL-17 & 23 targets).
  
  
• Sleep Quality.
  Short or fragmented sleep raises IL-6 and TNF-α. Consistent sleep timing, light management, and sleep-hygiene practices reduce these same cytokines.
  
  
• Environmental Exposures.
  Tobacco smoke, air pollution, and certain toxins increase TNF-α, IL-6, IL-17. Reducing exposures and improving indoor air can ease these pathways – similar to TNF, IL-6, and IL-17 drug effects.
  
  
• Physical Activity.
  Regular moderate exercise lowers TNF-α and IL-6 and raises IL-10, a powerful anti-inflammatory brake that no drug directly replicates.
  
  
• Key Insight.
  Drugs block one cytokine at a time. Lifestyle changes calm many at once in a milder way. Medication may be crucial early on; but as root drivers are addressed, many people can taper and sometimes replace drugs under medical supervision.

12) Working With Your Rheumatologist

Seek a rheumatologist who is open to combining lifestyle medicine with pharmaceuticals – someone who will help you use medication as a bridge while you do the deeper work that moves the disease. Also recognise that even lifestyle-focused clinicians may miss environmental or dietary factors unique to you. This site exists to map those root-cause levers and point to the practical steps that have helped many people achieve remission.

13) Summary 

Biologics and JAK inhibitors can be life-changing when inflammation is high and joint damage threatens, but they are not curative and carry serious risks and significant costs. The same immune pathways these drugs target can in many cases be repaired by Lifestyle and environmental changes. Use medication wisely, pursue root causes consistently, and plan for tapering once inflammation is truly low and stable – always with medical supervision.

References 

Guidelines, Reviews, and Mechanisms

• Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020.

• Singh JA, et al. 2016 ACR guideline for RA treatment; plus updates where applicable. Arthritis Care Res.

• Buch MH, et al. Biologic and targeted synthetic DMARDs in RA—mechanisms and management. Lancet. 2021.

• McInnes IB, Schett G. Cytokines in the pathogenesis of RA. Nat Rev Immunol.

• Taylor PC, et al. JAK inhibitors: mechanisms, efficacy, safety. Nat Rev Rheumatol.

• Choy EHS. IL-6 pathway in RA. Rheumatology (Oxford).

• Mease PJ, et al. IL-17/IL-23 pathways in psoriatic arthritis. Arthritis Rheumatol.

• van Vollenhoven R. Biologics in RA: clinical use and safety. Lancet.

Key Safety Data and Labels

• FDA Prescribing Information and Medication Guides for: adalimumab, etanercept, infliximab, golimumab, certolizumab, tocilizumab, sarilumab, secukinumab, ixekizumab, brodalumab (REMS), ustekinumab, guselkumab, risankizumab, rituximab (boxed warnings for infusion reactions, HBV reactivation, PML), abatacept.

• FDA Drug Safety Communications on JAK inhibitors (tofacitinib, baricitinib, upadacitinib) highlighting MACE, malignancy, VTE, and mortality signals.

• Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib vs TNF inhibitors (ORAL Surveillance). New England Journal of Medicine. 2022.

Effectiveness and Switching

• Cochrane reviews and pivotal trial programs for TNF, IL-6, IL-17, IL-12/23, IL-23, abatacept, rituximab, and JAK inhibitors (ACR20/50/70 responses, radiographic outcomes).

• Evidence favouring mechanism switch after TNF failure in RA.

Monitoring, Vaccination, Infection Prevention

• ACR and EULAR vaccination guidance for patients on immunosuppressive therapies (influenza, pneumococcal, COVID-19, recombinant zoster, hepatitis B; avoidance of live vaccines).

• HBV reactivation risk and monitoring protocols with rituximab and TNF inhibitors.

Lifestyle and Cytokines

• Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients.

• Hotamisligil GS. Inflammation and metabolic disease. Nature.

• Tilg H, Moschen AR. Gut microbiota and inflammation. Nat Rev Immunol.

• Irwin MR. Sleep and inflammation. Nat Rev Immunol.

• Slavich GM. Stress and inflammation. Clin Psychol Sci.

• Gleeson M, et al. Exercise, immunity, inflammation. J Appl Physiol.

• Holick MF. Vitamin D deficiency and immune dysfunction. New England Journal of Medicine.

• Environmental exposures and inflammation: ATS statements and umbrella reviews.

Costs and Access

• U.S. list/WAC price compendia, NADAC/AWP summaries, and public manufacturer resources for biologics and JAK inhibitors; payer and assistance program summaries.
  (Note: real patient costs vary widely by coverage, site of care, and assistance; always verify current local pricing.)

Disclaimer 

This page is educational and does not replace personal medical care. Starting, changing, tapering, or stopping any medicine must be done with your qualified healthcare professional. For legal and safety details, see the site’s Disclaimer page.